Nasdaq:COEP
Coeptis Therapeutics Holdings, Inc.
A pre-revenue clinical-stage biotech firm developing novel therapies for severe inflammatory diseases through a proprietary technology platform.
Key Metrics
Investment Thesis
Bull Case
An investor might buy COEP if they believe in the transformative potential of its pipeline candidates for severe inflammatory diseases and expect a successful clinical trial readout or strategic partnership deal. The current low share price could reflect a deep value opportunity if the company secures funding and demonstrates progress in bringing its novel therapeutics to market.
Bear Case
An investor should avoid COEP due to its negative cash flow, lack of revenue, and high reliance on dilutive share issuances to sustain operations. With current liabilities significantly exceeding current assets and no commercial products yet sold, the company is at risk of insolvency if it cannot secure further financing or achieve clinical milestones.
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings (COEP) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for severe inflammatory diseases such as Crohn's disease. The company leverages its proprietary technology platform to create targeted treatments, currently operating with limited revenue and relying heavily on equity financing to fund its research and development pipeline.
Analysis
Management Discussion
Management has successfully extended operations by raising over $5 million through financing activities, yet the company continues to burn approximately $6.6 million annually in cash from operations. The balance sheet shows a substantial retained earnings deficit of nearly $100 million, indicating that current assets are insufficient to cover current liabilities without external capital injections.
Industry Overview
The biopharmaceutical industry is characterized by long development cycles, high failure rates in clinical trials, and significant capital requirements before a product reaches market. Companies like Coeptis operate in a competitive landscape where proprietary technology and successful differentiation are essential to capture value from expensive R&D investments.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $34.2M | $21.5M | $10.1M |
| Operating Income | $-34.2M | $-21.5M | $-10.1M |
| R&D | $20.9K | $6.7M | $2.3M |
| G&A | $34.2M | $3.9M | $945.6K |
| Marketing | $8.3K | $12.7K | — |
| Stock-Based Comp | $0 | $477.5K | $1.1M |
| D&A | $1.0M | $1.0M | $1.0M |
| Depreciation | — | — | $845 |
| Other OpEx | $0 | $10.9M | $6.8M |
| Non-Operating Income | $-3.4M | $224.6K | $-822.9K |
| Interest Expense | $218.4K | $107.7K | — |
| Pre-Tax Income | $-37.6M | $-21.3M | $-10.9M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-37.6M | $-21.3M | $-9.8M |
| Discontinued Ops | $0 | $0 | $-1.1M |
| Net Income | $-37.6M | $-21.3M | $-10.9M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-37.6M | $-21.3M | $-10.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $3.9M | $5.2M | $1.1M |
| Accounts Receivable | $8.1K | $0 | — |
| Other Current Assets | $3.9M | $5.2M | — |
| Long-Term Assets | $4.0M | $2.8M | $7.9M |
| PP&E (Net) | $12.5K | $11.3K | $10.5K |
| Operating Leases | $58.9K | $97.6K | $59.8K |
| Other LT Assets | $3.9M | $2.7M | $7.8M |
| Total Assets | $7.9M | $8.1M | $8.9M |
| Current Liabilities | $1.8M | $3.0M | $4.5M |
| Accounts Payable | $99.0K | $1.4M | $1.3M |
| Current Leases | $41.6K | $38.0K | $42.3K |
| Other Current Liab | $1.5M | $975.0K | $2.5M |
| Long-Term Liabilities | $1.3M | $768.4K | $528.1K |
| Long-Term Debt | $150.0K | $150.0K | — |
| LT Operating Leases | $14.7K | $61.2K | $18.9K |
| Other LT Liab | $1.1M | $557.2K | $509.2K |
| Total Liabilities | $3.1M | $3.8M | $5.0M |
| Shareholders' Equity | $4.8M | $4.3M | $3.9M |
| Paid-In Capital | $70.5M | $91.7M | $103.0M |
| Retained Earnings | $-65.7M | $-87.4M | $-98.2M |
| Treasury Stock | $0 | $0 | $0 |
| Total L&E | $7.9M | $8.1M | $8.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-37.6M | $-21.3M | $-10.9M |
| Non-Cash Adjustments | $33.3M | $12.5M | $3.6M |
| Working Capital Changes | $447.2K | $1.6M | $581.2K |
| Cash from Operations | $-3.9M | $-7.2M | $-6.6M |
| Cash from Investing | $0 | $0 | $0 |
| Cash from Financing | $5.5M | $4.9M | $5.7M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $1.6M | $-2.3M | $-936.2K |
| Beginning Cash | $2.2M | $3.8M | $1.5M |
| Ending Cash | $3.8M | $1.5M | $532.9K |
Frequently Asked Questions
How does Coeptis Therapeutics Holdings, Inc. make money?
The company operates primarily within the pharmaceuticals segment, focusing on the discovery and development of small molecule therapeutics. Current financials indicate a singular focus on research and development activities rather than distinct commercial product lines or geographic segments, as no revenue has been generated to date.
What are the main risks for COEP?
The company faces extreme financial risk due to a continuous net loss of over $10 million and a lack of revenue, requiring frequent equity issuances to extend its cash balance. There is also significant operational risk associated with the high costs of drug discovery, potential failure in clinical trials, and the uncertainty of regulatory approval for their pipeline candidates.
What is COEP's competitive advantage?
The company's primary competitive advantage lies in its proprietary technology platform designed to develop novel oral therapies for unmet medical needs in inflammatory diseases. Additionally, the significant investment in paid-in capital provides a substantial cash runway, allowing the firm to advance multiple candidates through clinical trials without immediate commercial pressure.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.